Invesco S&P 500 Equal Weight Health Care ETF

RSPH

Market cap $753M

Launched on November 1, 2006, the Invesco S&P 500 Equal Weight Health Care ETF (RSPH) is a passively managed exchange traded fund designed to provide a broad exposure to the Healthcare - Broad segment of the equity market.

RSPH is an equal-weight ETF on the healthcare market that replicates the S&P 500 Equal Weight Health Care Index. Its composition makes it more diversified and gives more room for the mid-cap healthcare segment to emerge. This makes it, in my opinion, more sensitive to changes in monetary policy, and it is the reason for the underperformance that started in 2022.

The healthcare sector has experienced one of its most significant de-ratings in 35 years, with valuations now at a 30% discount to the broader market. Healthcare trades at historical valuation discounts across multiple metrics.

The Investment Committee give you thieir top stocks to watch for the second half.

A smart beta exchange traded fund, the Invesco S&P 500 Equal Weight Health Care ETF (RSPH) debuted on 11/01/2006, and offers broad exposure to the Health Care ETFs category of the market.

Designed to provide broad exposure to the Healthcare - Broad segment of the equity market, the Invesco S&P 500 Equal Weight Health Care ETF (RSPH) is a passively managed exchange traded fund launched on November 1, 2006.

Designed to provide broad exposure to the Health Care ETFs category of the market, the Invesco S&P 500 Equal Weight Health Care ETF (RSPH) is a smart beta exchange traded fund launched on 11/01/2006.

Looking for broad exposure to the Healthcare - Broad segment of the equity market? You should consider the Invesco S&P 500 Equal Weight Health Care ETF (RSPH), a passively managed exchange traded fund launched on 11/01/2006.

Making its debut on 11/01/2006, smart beta exchange traded fund Invesco S&P 500 Equal Weight Health Care ETF (RSPH) provides investors broad exposure to the Health Care ETFs category of the market.

Outlook for pharma sector as Trump pushes for regulatory changes. The impact of tariffs on drugmakers.